Previous studies have demonstrated a proapoptotic role for the transcription factor STAT3 in involuting murine mammary epithelium, resulting in delayed involution and lower levels of apoptosis in the STAT3 null gland relative to wild-type controls. As p53 was implicated in the eventual involution of the STAT3 null gland, we examined the effect of STAT3 loss in the mammary gland in a p53 null background. Combined loss of STAT3 and p53 severely perturbed involution, with hyperdelayed loss of epithelium and reappearance of adipocytes. The early apoptotic response was almost completely abrogated, although elevated levels of delayed apoptosis persisted at days 6, 17 and 4 weeks of involution in STAT3-p53 doubly null mammary glands. A 5.7-fold upregulation of the cyclin-dependent kinase inhibitor p21Waf1 at 3 days of involution in STAT3 null glands was abolished in STAT3-p53 doubly null glands -suggesting that the critical factor triggering delayed involution in the STAT3 null gland is a p53-dependent rise in p21Waf1 levels around day 3 of involution. Further, STAT3-p53 doubly null glands showed significantly higher levels of proliferation compared to STAT3 or p53 singly null (or wild-type) glands at days 6, 17 and 4 weeks of involution. Combined loss of STAT3 and p53 therefore results in hyperdelayed involution, demonstrating their synergistic physiological roles in normal involution. This inappropriate retention of p53-deficient cells may represent a novel mechanism of tumour predisposition.
Introduction
Constitutively activated members of the STAT transcription factor family, particularly STAT3, have been identified in an increasing number of human cancers, and the prospect of their therapeutic inhibition is attracting increasing interest (Darnell, 2002; Yu and Jove, 2004) . Another frequent requirement for cancer progression is loss of the p53 tumour suppressor's ability to activate the apoptotic cell death transcriptional programme, with the p53 gene being reported as mutant in around half of all cancers (Vousden and Lu, 2002; Yu and Jove, 2004) . Although activated STAT3 has an anti-apoptotic function in a range of cancers through the upregulation of Bcl-Xl gene expression (Catlett-Falcone et al., 1999) , conditional deletion of STAT3 in the murine mammary gland has yielded persuasive evidence for a proapoptotic role for STAT3 in the normal involution process. For example, delayed involution was observed in STAT3 null vs STAT3 wildtype glands, and significantly less apoptosis was observed at day 3 of involution in STAT3 null glands (Chapman et al., 1999) . Delayed mammary gland involution has also been observed in the p53 null BALB/c mouse (as have reduced levels of apoptosis) (Jerry et al., 1998) -although this delay in involution is much less apparent on a C57BL/6 background (Li et al., 1996) . We have previously identified a number of proteins that are deregulated in the STAT3 null gland, including insulin-like growth factor-binding protein-5 (IGFBP-5), STAT1, p53 and p21 (Chapman et al., 1999) . The elevated levels of these proteins implicates them in triggering the delayed involution of the STAT3 null mammary gland. To further investigate the potential role of p53 in this process, we have analysed the programme of involution in wild-type, p53 null, STAT3 null and STAT3-p53 doubly null backgrounds.
Results

Involution in STAT3-p53 doubly null mammary glands is hyperdelayed
Mice bearing a loxP flanked STAT3 allele (Takeda et al., 1997) and the BLG-Cre transgene (Selbert et al., 1998) were intercrossed with mice bearing a null p53 allele (Clarke et al., 1993) to generate cohorts of mice segregating for all three alleles. The programme of involution was then studied in mice with the following genotypes:
(hereafter termed wild type); BLG-Cre þ STAT3 þ / þ p53 À/À (hereafter termed p53 null); BLG-Cre þ STAT fl/À p53 À/À (hereafter termed STAT3-p53 double null). The extent of involution was assessed at days 3, 6, 17 and at 4 weeks following a forced wean. Examination of haematoxylin plus eosin (H þ E)-stained mammary gland sections indicated weakly delayed involution in the absence of p53 and a more marked retardation in the STAT3 null glands (Figure 1 ), consistent with previous reports (Jerry et al., 1998; Chapman et al., 1999) . However, the STAT3-p53 doubly null glands showed a severe phenotype, such that glands at day 17 still retained ductal structures and showed retained milk protein.
In order to assess the differences in the extent of involution between genotypes, we quantified the proportion of gland occupied by adipocytes and mammary epithelium (Figure 2 ). By day 3 of involution, wild-type glands showed approximately 40% repopulation by adipocytes. Both the p53 null and STAT3 null glands showed much lower adipocyte content, and the STAT3-p53 doubly null glands were still almost totally composed of epithelium (99.4%). The p53 null, STAT3 null and STAT3-p53 doubly null glands all showed a significantly higher proportion of epithelium remaining than wild-type glands (95% confidence interval, MannWhitney U-test Po0.05), and although p53 null and STAT3 null glands were not different from each other (Po0.05), STAT3-p53 doubly null glands showed a higher proportion of epithelium remaining compared to either of the singly nulls (Po0.05) (Figure 2a ). At day 6 of involution, wild-type glands were approximately midway between the lactating and fully involuted states, while p53 deficiency had no apparent impact upon gland composition. However, at the day 6 time point, STAT3 null glands showed a slightly reduced adipocyte content, while STAT3-p53 doubly null glands retained a higher (Po0.05) proportion of epithelium (79%) compared to STAT3 null glands (61%). In contrast, the proportions of epithelium in wild type, p53 null and STAT3 null glands were not significantly different (Po0.05) (Figure 2b ). At day 17, the wild-type glands were remodelled, while both single nulls showed reduced adipocyte content, a feature more marked in the STAT3 nulls, with wild-type glands showing a lower proportion of epithelium than p53 null glands (Po0.05), which in turn showed a lower proportion of epithelium than STAT3 null glands (Po0.05). The double null glands again showed a strong perturbation of involution with nearly 70% of the gland still occupied by epithelium ( Figure 2c ) -a higher proportion than in STAT3 singly null glands (Po0.05). By 4 weeks of involution, p53 null glands had essentially completely involuted, whereas the STAT3 nulls were delayed relative to p53 null glands Full Figure 1 Grossly delayed progress of involution in the STAT3-p53 doubly null mammary gland. H þ E-stained sections from 3-day, 6-day, 17-day and 4-week (full) involution time points for wild-type, p53 null, STAT3 null and STAT3-p53 doublly null mammary glands (Po0.05), and STAT3-p53 double nulls were further delayed (Po0.05) (Figure 2d ). To determine if the perturbed involution was a direct reflection of reduced ability to engage apoptosis, we next scored the frequency of apoptotic bodies in H þ Estained sections (Figure 3) . Apoptosis in the STAT3-p53 doubly null glands was almost completely repressed at day 3 of involution, when apoptotic activity is typically maximal in wild-type glands. Thus, at day 3 of involution, wild-type glands showed an apoptotic index of 4.65%. In contrast, STAT3-p53 doubly null glands showed a lower apoptotic index (Po0.05) of only 0.97% at day 3, essentially basal apoptotic activity (Figure 3a) . The p53 and STAT3 singly null glands showed intermediate behaviour (3.95 and 1.88% apoptosis, respectively), with STAT3 null glands showing fewer apoptoses than p53 null glands (Po0.05). However, there were no differences between wild-type and p53 null glands (Po0.05) or between STAT3 null and STAT3-p53 doubly null glands (Po0.05). Interestingly, the indicating a greatly delayed remodelling in the doubly null glands that remained incomplete even at 4 weeks of involution. (Figure 3d ). Thus, at day 6 of involution, apoptotic indices decreased in the order STAT3-p53 doubly null, STAT3 null, p53 null and wild-type glands with significant differences between each pair of indices (Po0.05). By day 17 of involution, although the apoptotic frequencies in wild type, p53 null and STAT3 null glands were not different from each other (Po0.05), they were all lower than the apoptotic frequency in STAT3-p53 doubly null glands (Po0.05).
A similar pattern was seen at 4 weeks (full) involution with a higher frequency in the STAT3-p53 doubly null gland relative to the other three types of glands (Po0.05) -reflecting continuing, but greatly delayed remodelling.
Molecular analysis shows failed induction of p21Waf1 in the STAT-p53 doubly mutant glands RIPA extracts from day 3 and 6 involution mammary glands were analysed by immunoblotting and subsequently quantified by densitometry. The mean values at each genotype/time point were then divided by the proportion of mean cytokeratin 18 immunoreactivity remaining under those conditions (the maximum mean cytokeratin 18 value of the full genotype/time point sample sets being normalized as 1 to correct for the proportion of epithelium remaining). Immunoblots for STAT3 corrected for the proportion of epithelium confirmed the almost total loss of functional STAT3 and of tyrosine phosphorylated STAT3 in the STAT3 null and STAT3-p53 doubly null glands at both 3 and 6 days of involution (Figure 4a, b) . Thus, as expected, the compensated levels of total STAT3 and tyrosine phosphorylated STAT3 were lower in STAT3 null and STAT3-p53 doubly null glands relative to wild-type glands (Po0.05) at both days 3 and 6 of involution. Figure 4 Immunoblotting of apoptosis-related proteins to identify the species responsible for hyper-delayed involution in the STAT3-p53 doubly null mammary gland. The dramatic upregulation of p21Waf 1 expression in the day 3 involution STAT3 null gland is totally abolished in the STAT3-p53 doubly null gland. We first analysed expression levels of candidate regulators of apoptosis within the mammary gland. Analysis of the Bcl-Xl protein after compensation for the proportion of cytokeratin 18 remaining showed a modest (1.4-fold), but significant (Po0.05) fall in Bcl-Xl expression in STAT3-p53 doubly null glands relative to STAT3 singly null glands at day 3 of involution. In contrast, by day 6 of involution, while compensated levels of Bcl-Xl expression had fallen still further, Bcl-Xl expression in STAT3-p53 doubly null glands was modestly (1.5-fold) upregulated compared to STAT3 singly null glands (Po0.05) (Figure 4c ). Similarly to Bcl-Xl, analysis of Bcl-Xs protein expression after compensation showed a small (1.3-fold), but significant (Po0.05) fall in Bcl-Xs expression in STAT3-p53 doubly null glands compared to STAT3 singly null glands at day 3 of involution ( Figure 4d ). Similar analysis of Bcl-Xs expression at day 6 of involution showed a 2.8-fold upregulation (Po0.05) in STAT3-p53 doubly null vs STAT3 singly null glands. As Bcl-Xl and Bcl-Xs proteins failed to show any major differences in their regulation in STAT3 null vs the STAT3-p53 doubly null mammary glands at either days 3 or 6 of involution (Figure 4c, d) , this suggests that they are not involved in triggering the STAT3 null gland delayed involution. Compensated expression levels for the proapoptotic Bax protein showed a 2.4-fold downregulation in STAT3-p53 doubly null glands at day 3 of involution compared to STAT3 null glands (Po0.05) (Figure 4e ), while compensated expression levels for Bax at day 6 of involution showed a modest (1.5-fold) increase (Po0.05) in STAT3-p53 doubly null glands compared to STAT3 singly null glands. The high compensated expression level for Bax in day 3 involution STAT3 null glands, and the size and statistical significance of the fall in Bax expression in STAT3-p53 doubly null glands suggests that Bax downregulation might have some importance in causing further delay in involution in STAT3-p53 doubly null glands.
We have previously identified three other candidate mechanisms, which may drive the delayed involution in the STAT3 null mammary gland: p53/p21Waf1, STAT1 and IGFBP-5 (Chapman et al., 1999) . We therefore investigated the patterns of expression of these genes in the doubly mutant glands. Our previous analysis had shown that there was a marked upregulation of STAT1 expression at days 2 and 3 of involution in the STAT3 null glands (Chapman et al., 1999) . If upregulation of STAT1 were indeed key to driving the delayed involution in the absence of STAT3, we would have predicted a corresponding delayed induction of STAT1 in the STAT3-p53 doubly null glands. However, comparing the STAT3 null with STAT3-p53 doubly null glands revealed only very modest changes in the expression level of (the proapoptotic) STAT1 protein (Figure 4f) . Thus, while STAT1 expression at day 3 of involution in STAT3-p53 doubly null glands was lower than in STAT3 null glands (Po0.05), the size of the decrease was very modest (1.3-fold). While at day 6 of involution, STAT1 expression in STAT3-p53 doubly null glands was higher than in STAT3 null glands (Po0.05), although the size of the increase was again very modest (1.8-fold) -suggesting STAT1 induction is not a prerequisite for STAT3-independent involution.
We also analysed levels of activated, tyrosine phosphorylated, STAT1 as this was again upregulated in STAT3 null glands at days 3 and 6 of involution. However, comparing the STAT3 null and STAT3-p53 doubly null glands revealed only very modest changesa 1.3-fold fall in the compensated expression level of tyrosine phosphorylated STAT1 in STAT3-p53 doubly null glands vs STAT3 null glands at day 3 (Po0.05) and a modest twofold increase in activated STAT1 in the doubly null gland at day 6 of involution (Po0.05) (Figure 4g ). This again suggests that upregulation of the proapoptotic STAT1 is not the primary mechanism by which involution is eventually triggered in the STAT3 null mammary gland.
A second candidate molecule identified in the earlier study was IGFBP-5, which has been suggested to induce epithelial apoptosis and is upregulated at the start of involution (Tonner et al., 2002) . As before (Chapman et al., 1999) , after compensation for the proportion of epithelium remaining, IGFBP-5 expression was downregulated in the STAT3 null relative to the wild-type mammary gland. However, comparison of the STAT3 null and STAT3-p53 doubly null glands showed no differences in IGFBP-5 regulation at days 3 or 6 of involution (Figure 4h ), suggesting that IGFBP-5 is not the key regulator of eventual involution of the STAT3 null gland.
Previous studies demonstrated that the loss of STAT3 was associated with a dramatic upregulation of p53 and p21Waf1 expression at days 2 and 3 of involution (Chapman et al., 1999) , and indeed the principal hypothesis we address in the double mutants is that p53 mediates the eventual involution through a p21Waf1-dependent pathway. Immunoblots directed against p21Waf1 after compensation for the proportion of epithelium indeed showed that the 5.7-fold p21Waf1 upregulation in day 3 involution STAT3 null glands relative to wild-type glands was completely abolished in STAT3-p53 doubly null glands (0.86 expression level relative to wild-type glands) with p21Waf1 expression in STAT3-p53 doubly null glands being 6.7-fold lower than in STAT3 null glands (Figure 4i ). The compensated p21Waf1 expression level in STAT3-p53 doubly null glands is lower (Po0.05) than in STAT3 null glands at both days 3 and 6 of involution (although by day 6 of involution the p21Waf1 downregulation in STAT3-p53 doubly null relative to STAT3 null glands has fallen to a more modest 1.9-fold). With evidence for a requirement for p21Waf1 for the eventual induction of apoptosis (Duttaroy et al., 1997) , this seems to be a convincing mechanism for the further delay in involution in the doubly null gland. The case for a p21Waf1-dependent apoptosis pathway is strengthened by the recent finding that the absence of p19Arf (which increases p53 stability and function in the nucleus (Zhang et al., 1998) ) from mammary epithelial cells also caused a delay in involution which was correlated with a downregulation of p21Waf1 and decreased apoptosis (Yi et al., 2004) .
Enhanced proliferation in STAT3-p53 doubly null glands even at 4 weeks of involution
The hyperdelayed involution seen in STAT3-p53 doubly null glands might also reflect differences in cellular proliferation relative to p53 and STAT3 singly null and wild-type glands. Mammary gland sections were stained for the proliferation marker Ki-67 and the percentage of epithelial nuclei showing detectable immunoreactivity recorded. The proliferation indices seen at day 3 of involution were similar for STAT3-p53 doubly null and p53 and STAT3 singly null glands and all were higher (Figure 5a ). By day 6 of involution, the proliferation levels in STAT3-p53 doubly null glands were higher than in either the p53 null or STAT3 null glands (Po0.05). All three gland types showed higher indices than wild-type glands (Po0.05). At day 17 of involution, proliferation indices in STAT3-p53 doubly null glands were higher than in p53 null, STAT3 null and wild-type glands (Po0.05). Proliferation levels in p53 null and STAT3 null glands were almost identical (P ¼ 1.000). At this time point all three null gland types (STAT3-p53, p53 and STAT3 null) showed higher levels of proliferation than wildtype glands (Po0.05). At 4 weeks of involution (28 days), indices in STAT3-p53 doubly null glands remained higher than in p53 null, STAT3 null and wild-type (Po0.05) glands (Figure 5a, b) . At this time point, p53 null gland proliferation was lower than in STAT3 null glands (Po0.05). Again, as before, the proliferation indices at 4 weeks of involution in STAT3-p53 doubly null, p53 null and STAT3 null glands were higher than in wild-type glands (Po0.05). Representative fields from Ki-67-stained mammary gland sections from wild-type, p53 null, STAT3 null and STAT3-p53 doubly null glands are shown (Figure 5b ).
Discussion
The hyperdelayed involution of the STAT3-p53 doubly null murine mammary gland reported here and its molecular mechanisms, the loss of the p53-dependent upregulation of p21Waf1 expression and protracted, elevated levels of epithelial proliferation clearly has ramifications for the normal physiological control of apoptosis within the mammary gland, but may also have important implications for mammary tumour formation. We show that the deletion of physiologically normal cells during involution normally requires functional STAT3, but that in the absence of STAT3 the apoptotic programme can default to a p53/p21Waf1 pathway. In addition to the failed upregulation of p21Waf1 as a mechanism underlying the hyperdelayed involution, there may also be a role for downregulation of proapoptotic Bax. In the absence of both the STAT3 and p53 pathways, involution is grossly perturbed, with remodelling of the gland still incomplete 4 weeks after a forced wean, with the consequent aberrant retention of epithelial cells. These findings raise the possibility that failed deletion of cells and continuing mammary epithelial proliferation may be a predisposing factor towards neoplasia.
This hypothesis has already been addressed in a number of different cellular systems, and although there is conflicting data (Sansom and Clarke, 2000) , it is clear that at least in some systems the failure of a normal apoptotic programme does increase the predisposition to neoplasia (Griffiths et al., 1997; Toft et al., 1999) . Our data suggest that STAT3 deficiency may predispose to mammary neoplasia either through the failed deletion of de novo p53-deficient cells, or by the emergence of deathresistant STAT3-deficient clones within a p53-deficient environment. One of the relevant questions here is therefore whether failure of the normal physiological involution programme will also predispose to neoplasia, a question we are currently addressing by an examination of ageing cohorts of singly and doubly null animals.
The possibility that STAT3 deficiency may predispose to neoplasia in the mammary gland appears to be in direct contradiction to the recognized association between constitutive activation of STAT3 and a wide range of human cancers, including breast cancers (Yu and Jove, 2004) . However, the two potential protumour activities of STAT3 deficiency and activation may represent completely separate pathways, such that a role for activated STAT3 in tumourigenesis does not rule out a similar tumour promoting role for STAT3 deficiency.
Materials and methods
Generation and genotyping of mouse strains
Mice bearing the STAT3 null and floxed alleles were the generous gift of Professor S Akira (Takeda et al., 1997 (Takeda et al., , 1998 . The generation of mice carrying the p53 null allele and Cre recombinase under the transcriptional control of the ovine b-lactoglobulin (BLG) promoter has been described previously (Clarke et al., 1993; Selbert et al., 1998) . Murine genomic DNA was prepared using a Puregene kit (Gentra Systems, MN, USA) and genotyped by PCR using primers specific for the wild-type vs null p53, STAT3 wild-type vs floxed and STAT3 null alleles and the Cre recombinase transgene. Mice used in the study were outbred and segregated for the C57BL6/ J, 129/Ola and C3 H genomes. Siblings were used as controls.
Involution and harvesting of experimental mice
Pregnant females were moved to individual cages before littering. If necessary, the litter size was increased to 8 by crossfostering equivalent aged pups. Litters were allowed to suckle for 10 days, then removed and females killed at days 3, 6, 17 or 28 of involution. At least three independent females were generated for each genotype/involution time point combination and their glands harvested. A small part of each mammary gland was taken into formal-saline and quick-fixed overnight at 41C before paraffin-embedding the next day, for subsequent staining with H þ E. The remainder was frozen immediately in liquid nitrogen, and then stored at À801C. Frozen glands were crushed twice to a fine powder in liquid nitrogen, and then extracted with 400ml of RIPA buffer (50 mM Tris.HCl, 150 mM NaCl, 1% v/v Nonidet P40, 0.5% w/v sodium deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, plus 1 protease inhibitor cocktail tablet (Roche, Complete Mini) per 10 ml of RIPA buffer). The mixture was then sheared repeatedly through a 25-gauge hypodermic needle, centrifuged at 10 000 g for 10 min at 41C, and the supernatant extract recovered, aliquoted, frozen in liquid nitrogen and stored at À801C.
Measurements of apoptosis and percentages of fat and epithelium
Scoring of apoptosis frequencies was performed using morphological criteria on fields of H þ E-stained glands from at least three independent mice. This method has previously been validated to accurately reflect levels of apoptosis through comparison with both Tunel staining and staining using an antibody against activated caspase 3 ( Chapman et al., 1999; Sansom and Clarke, 2000) . The relative areas of fat and epithelium in each field were measured using Image Grabber PCI (Neotech Ltd., London, UK) and Aequitas IA (DDL Ltd., Cambridge, UK) software packages. All statistical analysis was performed using the Mann-Whitney U-test.
Immunoblotting analysis
Protein concentrations of RIPA extracts were measured using the Bio-Rad DC (Detergent Compatible) protein assay system. Extracts from three independent sets of mammary glands were resolved on either 10 or 15% SDS-PAGE gels as appropriate under reducing conditions. The amounts of extract protein per lane used for the following targets were: tyrosine phosphorylated STAT3, 15 mg; STAT3, 10 mg; cytokeratin 18, 15 mg; IGFBP-5, 30 mg; tyrosine phosphorylated STAT1, 15 mg; STAT1, 15 mg; p21Waf1, 30 mg; Bax, 10 mg; Bcl-Xs/l, 10 mg. The separated proteins were then transferred to polyvinylidene difluoride (PVDF) (Millipore, Immobilon P) membranes by wet electroblotting, and the membranes then incubated in blocking buffer (TBS, 0.1% v/v Tween 20, 10% nonfat dried milk). Membranes were then incubated with the following primary antibodies diluted in blocking buffer -tyrosine phosphorylated STAT3 (Cell Signaling Technologies, #9131, 1 : 1000), total STAT3 (Cell Signaling Technologies, #9132, 1 : 200), cytokeratin 18 (Progen Ks18.04, 1 : 500), IGFBP-5 (Upstate Biotechnology, #06-110, 1 : 1000), tyrosine phosphorylated STAT1A and B (Cell Signaling Technologies, #9171, 1 : 200), total STAT1A and B (Cell Signaling Technologies, #9172, 1 : 200), p21Waf1 (Oncogene Research Products, Ab5 PC55, 1 : 100), Bax (Santa Cruz, sc-493, 1 : 1000), Bcl-Xs/l (Santa Cruz, sc-1041, 1 : 200). The membranes were then washed three times with blocking buffer (10 ml for 10 min). HRP-conjugated secondary antibodies (Amersham, 1 : 2000) were diluted in blocking buffer, and then incubated with membranes for 1 h at room temperature. Membranes were then washed, incubated with chemiluminescence detection reagents (Amersham, ECL Plus) and exposed to X-ray film (Amersham). The intensities of ECL signals were then quantitated using QuantiScan software (Biosoft, Cambridge, UK, Ferguson, MO, USA).
Ki-67 Immunohistochemistry
Mammary gland sections were analysed from each of three independent females for each genotype/involution timepoint combination. Antigens were unmasked by heating slides to 1001C in citrate buffer (1 Â , Lab Vision) for 30 min, and the slides allowed to cool. Slides were washed three times in Trisbuffered saline (Sigma), 0.1% v/v Tween-20 (Sigma) (TBS/T) and then incubated with TBS/T, 20% normal rabbit serum for 30 min at room temperature. Slides were then incubated with anti-Ki-67 MAb (Vector Laboratories, VP-K452, Clone MM1, 1 : 20, diluted in TBS/T, 20% normal rabbit serum) for 1 h at room temperature. Slides were washed, and then incubated with biotinylated rabbit anti-mouse secondary antibody (DAKO, 1 : 200, diluted in TBS/T, 20% normal rabbit serum) for 30 min at room temperature. Slides were washed, incubated with Vectastain Elite ABC-Horseradish peroxidase complex (Vector Laboratories) for 30 min at room temperature, washed again, and then incubated with DAB substrate plus chromogen (Lab Vision). Colour development was allowed to proceed for 17 min, and then the reaction was terminated by washing the slides and nuclei counterstained for 30 s in haematoxylin.
